Exact Mass: 419.2209

Exact Mass Matches: 419.2209

Found 43 metabolites which its exact mass value is equals to given mass value 419.2209, within given mass tolerance error 0.0002 dalton. Try search metabolite list with more accurate mass tolerance error 4.0E-5 dalton.

Adimolol

1-(3-{[2-hydroxy-3-(naphthalen-1-yloxy)propyl]amino}-3-methylbutyl)-2,3-dihydro-1H-1,3-benzodiazol-2-one

C25H29N3O3 (419.2209)

C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist

(4-((5,6-Diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid

2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}acetic acid

C25H29N3O3 (419.2209)

Maybridge3_001817

C25H29N3O3 (419.2209)

7-hydroxypleurostyline

C25H29N3O3 (419.2209)

MRE-269

[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-acetic acid

C25H29N3O3 (419.2209)

MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist.

PD-L1 inhibitor 1

C25H29N3O3 (419.2209)

N-[2-(4-morpholinyl)ethyl]-2-(4-propan-2-yloxyphenyl)-4-quinolinecarboxamide

C25H29N3O3 (419.2209)

(2S,3S,4R)-2-cyano-N-cyclohexyl-4-(hydroxymethyl)-3-[4-(4-methoxyphenyl)phenyl]azetidine-1-carboxamide

C25H29N3O3 (419.2209)

(2S,3R,4R)-2-cyano-N-cyclohexyl-4-(hydroxymethyl)-3-[4-(4-methoxyphenyl)phenyl]-1-azetidinecarboxamide

C25H29N3O3 (419.2209)

(2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-N-[(1R)-1-phenylethyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide

C25H29N3O3 (419.2209)

(2S,3S,3aR,9bR)-3-(hydroxymethyl)-7-[(E)-2-phenylethenyl]-2-(piperidine-1-carbonyl)-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizin-6-one

C25H29N3O3 (419.2209)

(2S,3S,4S)-2-cyano-N-cyclohexyl-4-(hydroxymethyl)-3-[4-(4-methoxyphenyl)phenyl]-1-azetidinecarboxamide

C25H29N3O3 (419.2209)

(2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-N-[(1R)-1-phenylethyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide

C25H29N3O3 (419.2209)

(2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-N-[(1S)-1-phenylethyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide

C25H29N3O3 (419.2209)

(2S,3S,3aR,9bR)-7-(cyclopenten-1-yl)-3-(hydroxymethyl)-6-oxo-N-[(1S)-1-phenylethyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide

C25H29N3O3 (419.2209)

(1R,9S,10S,11S)-12-(cyclopropylmethyl)-11-(3,4-dihydro-1H-isoquinoline-2-carbonyl)-10-(hydroxymethyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one

C25H29N3O3 (419.2209)

(2R,3S,4R)-2-cyano-N-cyclohexyl-4-(hydroxymethyl)-3-[4-(4-methoxyphenyl)phenyl]-1-azetidinecarboxamide

C25H29N3O3 (419.2209)

1-[(1R,2aR,8bR)-4-[cyclohexyl(oxo)methyl]-1-(hydroxymethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-2-(2-pyridinyl)ethanone

C25H29N3O3 (419.2209)

(1S,9R,10R,11R)-12-(cyclopropylmethyl)-11-(3,4-dihydro-1H-isoquinoline-2-carbonyl)-10-(hydroxymethyl)-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one

C25H29N3O3 (419.2209)

[(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]-phenylmethanone

C25H29N3O3 (419.2209)

(6S,7R,8R)-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-2-phenylethenyl]phenyl]-N-propan-2-yl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

C25H29N3O3 (419.2209)

(6R,7S,8S)-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-2-phenylethenyl]phenyl]-N-propan-2-yl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

C25H29N3O3 (419.2209)

cyclohexyl-[(2R,3S)-2-(hydroxymethyl)-1-[oxo(3-pyridinyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]methanone

C25H29N3O3 (419.2209)

cyclohexyl-[(2S,3S)-2-(hydroxymethyl)-1-[oxo(3-pyridinyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]methanone

C25H29N3O3 (419.2209)

(2R,3R,4R)-2-cyano-N-cyclohexyl-4-(hydroxymethyl)-3-[4-(4-methoxyphenyl)phenyl]-1-azetidinecarboxamide

C25H29N3O3 (419.2209)

1-[(1R,2aS,8bS)-4-[cyclohexyl(oxo)methyl]-1-(hydroxymethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-2-(2-pyridinyl)ethanone

C25H29N3O3 (419.2209)

1-[(1S,2aS,8bS)-4-[cyclohexyl(oxo)methyl]-1-(hydroxymethyl)-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-2-(2-pyridinyl)ethanone

C25H29N3O3 (419.2209)

1-[(1S)-1-(hydroxymethyl)-7-methoxy-1,9-dimethyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-2-phenylethanone

C25H29N3O3 (419.2209)

1-[(1R)-1-(hydroxymethyl)-7-methoxy-1,9-dimethyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-2-phenylethanone

C25H29N3O3 (419.2209)

[(1R)-1-(hydroxymethyl)-7-methoxy-1-methyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]-phenylmethanone

C25H29N3O3 (419.2209)

[(1S)-1-(hydroxymethyl)-7-methoxy-1-methyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]-phenylmethanone

C25H29N3O3 (419.2209)

(6S,7S,8S)-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-2-phenylethenyl]phenyl]-N-propan-2-yl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

C25H29N3O3 (419.2209)

(6S,7S,8R)-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-2-phenylethenyl]phenyl]-N-propan-2-yl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

C25H29N3O3 (419.2209)

(6R,7R,8R)-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-2-phenylethenyl]phenyl]-N-propan-2-yl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

C25H29N3O3 (419.2209)

(6R,7R,8S)-8-(hydroxymethyl)-2-oxo-7-[4-[(E)-2-phenylethenyl]phenyl]-N-propan-2-yl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide

C25H29N3O3 (419.2209)

cyclohexyl-[(2R,3R)-2-(hydroxymethyl)-1-[oxo(3-pyridinyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]methanone

C25H29N3O3 (419.2209)

cyclohexyl-[(2S,3R)-2-(hydroxymethyl)-1-[oxo(3-pyridinyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]methanone

C25H29N3O3 (419.2209)

ACT-333679

C25H29N3O3 (419.2209)

A member of the class of pyrazines that is {4-[(propan-2-yl)(pyrazin-2-yl)amino]butoxy}acetic acid carrying two additional phenyl substituents at positions 5 and 6 on the pyrazine ring. The active metabolite of selexipag, an orphan drug used for the treatment of pulmonary arterial hypertension.